Semiannual Securities Report — FY2026 H1
What Techno Medica Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-12View the original on EDINET
How much it says
46Typical
What moved here
4named for the first time
Its own wording
14terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim accounting period, revenue increased 8.5% year on year to ¥4,453.648 million, while operating profit increased to ¥468.211 million, up 75.7% year on year. The company also paid dividends and repurchased shares, and cash and cash equivalents at the end of the period amounted to ¥8,438.760 million.
Komori's summary of this document, not the document's own words.46Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
61
Detailed
40
Thin
82
Very detailed
75
Very detailed
12
Almost nothing
12
Almost nothing
55
Typical
67
Detailed
7
Almost nothing
35
Thin
50
Typical
R&D spend0百万円Money spent making new things.
Cash left over1百万円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.